Identification

Summary

Diflorasone is a topical corticosteroid used to treat the symptoms of various inflammatory skin conditions that cause erythema, pruritus, and discomfort.

Brand Names
Apexicon, Florone, Psorcon
Generic Name
Diflorasone
DrugBank Accession Number
DB00223
Background

Diflorasone is a topical corticosteroid used to treat itching and inflammation of the skin.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 410.4515
Monoisotopic: 410.190480416
Chemical Formula
C22H28F2O5
Synonyms
  • (6α,11β,16β)-6,9-difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
  • Diflorasona
  • Diflorasone
  • Diflorasonum

Pharmacology

Indication

For relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Like other topical corticosteroids, diflorasone has anti-inflammatory, antipruritic, and vasoconstrictive properties. Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Diflorasone is a potent topical corticosteroid that should not be used with occlusive dressings. It is recommended that treatment should be limited to 2 consecutive weeks and therapy should be discontinued when adequate results have been achieved.

Mechanism of action

The precise mechanism of the antiinflammatory activity of topical steroids in the treatment of steroid-responsive dermatoses, in general, is uncertain. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Humans
Absorption

Topical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may also increase percutaneous absorption.

Volume of distribution

Not Available

Protein binding

Bound to plasma proteins in varying degrees.

Metabolism

Metabolized, primarily in the liver, and then excreted by the kidneys.

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Topically applied diflorasone can be absorbed in sufficient amounts to produce systemic effects. Symptoms of overdose include thinning of skin and suppression of adrenal cortex (decreased ability to respond to stress).

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcarboseThe risk or severity of hyperglycemia can be increased when Diflorasone is combined with Acarbose.
AcetohexamideThe risk or severity of hyperglycemia can be increased when Diflorasone is combined with Acetohexamide.
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Diflorasone is combined with Acetyldigitoxin.
AlbiglutideThe risk or severity of hyperglycemia can be increased when Diflorasone is combined with Albiglutide.
Allogeneic processed thymus tissueThe therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Diflorasone.
AlogliptinThe risk or severity of hyperglycemia can be increased when Diflorasone is combined with Alogliptin.
AminoglutethimideThe therapeutic efficacy of Diflorasone can be decreased when used in combination with Aminoglutethimide.
BendroflumethiazideThe risk or severity of electrolyte imbalance can be increased when Diflorasone is combined with Bendroflumethiazide.
BenzthiazideThe risk or severity of electrolyte imbalance can be increased when Diflorasone is combined with Benzthiazide.
BromocriptineThe risk or severity of hyperglycemia can be increased when Diflorasone is combined with Bromocriptine.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
No interactions found.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Diflorasone diacetate7W2J09SCWX33564-31-7BOBLHFUVNSFZPJ-JOYXJVLSSA-N
International/Other Brands
Florone E / Maxiflor
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
FloroneCream0.5 mg/1gTopicalPharmacia and Upjohn Division of Pfizer2006-02-06Not applicableUS flag
Florone Crm 0.05%Cream.05 %TopicalUpjohn1980-12-311998-08-12Canada flag
Florone Ont 0.05%Ointment.05 %TopicalUpjohn1980-12-311998-08-12Canada flag
PsorconCream0.5 mg/60gTopicalDermik Laboratories, Inc.2009-01-16Not applicableUS flag
PsorconOintment0.5 mg/1gTopicalDermik Laboratories, Inc.2006-02-06Not applicableUS flag
PsorconOintment0.5 mg/1gTopicalPhysicians Total Care, Inc.1985-08-282002-06-30US flag
Psorcon ECream0.5 mg/1gTopicalDermik Laboratories, Inc.2007-08-04Not applicableUS flag
Psorcon EOintment0.5 mg/1gTopicalDermik Laboratories, Inc.2006-02-06Not applicableUS flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
ApexiConOintment0.5 mg/1gTopicalFougera Pharmaceuticals Inc.2009-09-302014-05-31US flag
ApexiCon ECream0.5 mg/1gTopicalPharmaDerm a division of Fougera Pharmaceuticals Inc.2002-12-20Not applicableUS flag
ApexiCon ECream0.5 mg/1gTopicalPharma Derm, A Division Of Fougera Pharmaceuticals Inc.2009-09-302014-06-30US flag
Diflorasone DiacetateCream0.5 mg/1gTopicalEmerald Therapeutics, LLC2000-04-24Not applicableUS flag
Diflorasone DiacetateCream0.5 mg/1gTopicalTaro Pharmaceuticals U.S.A., Inc.2000-04-24Not applicableUS flag
Diflorasone DiacetateOintment0.5 mg/1gTopicalTeligent Pharma, Inc.2018-06-13Not applicableUS flag
Diflorasone DiacetateCream0.5 mg/1gTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.1998-03-30Not applicableUS flag
Diflorasone DiacetateOintment0.5 mg/1gTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.1999-04-27Not applicableUS flag
Diflorasone DiacetateOintment0.5 mg/1gTopicalRising Pharmaceuticals, Inc.2017-02-27Not applicableUS flag
Diflorasone DiacetateOintment0.5 mg/1gTopicalInnovida Pharmaceutique Corporation2018-08-15Not applicableUS flag

Categories

ATC Codes
D07AC10 — Diflorasone
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Hydroxysteroids
Direct Parent
21-hydroxysteroids
Alternative Parents
Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 11-beta-hydroxysteroids / 17-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Tertiary alcohols / Alpha-hydroxy ketones / Secondary alcohols
show 8 more
Substituents
11-beta-hydroxysteroid / 11-hydroxysteroid / 17-hydroxysteroid / 20-oxosteroid / 21-hydroxysteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 6-halo-steroid / 9-halo-steroid / Alcohol
show 24 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
11beta-hydroxy steroid, 17alpha-hydroxy steroid, glucocorticoid, 20-oxo steroid, fluorinated steroid, 3-oxo-Delta(1),Delta(4)-steroid, 21-hydroxy steroid (CHEBI:59750)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
T2DHJ9645W
CAS number
2557-49-5
InChI Key
WXURHACBFYSXBI-XHIJKXOTSA-N
InChI
InChI=1S/C22H28F2O5/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-19(15,2)21(14,24)17(27)9-20(13,3)22(11,29)18(28)10-25/h4-5,7,11,13-14,16-17,25,27,29H,6,8-10H2,1-3H3/t11-,13-,14-,16-,17-,19-,20-,21-,22-/m0/s1
IUPAC Name
(1R,2S,8S,10S,11S,13S,14R,15S,17S)-1,8-difluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES
[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C

References

Synthesis Reference

Lincoln, F.H., Schneider, W.P. and Spero, G.B.; U.S. Patent 3,557,158; January 19,1971; assigned to The Upjohn Company. Ayer, D.E., Schiagel, C.A. and Flynn,G.L.; US. Patent 3,980,778; September 14,1976; assigned to The Upjohn Co.

General References
  1. FDA Approved Drug Products: PSORCON (diflorasone diacetate) ointment [Link]
Human Metabolome Database
HMDB0014368
KEGG Drug
D07827
PubChem Compound
71415
PubChem Substance
46504519
ChemSpider
64505
RxNav
91311
ChEBI
59750
ChEMBL
CHEMBL1201380
ZINC
ZINC000005752191
Therapeutic Targets Database
DAP001184
PharmGKB
PA164749408
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Diflorasone
FDA label
Download (26.8 KB)
MSDS
Download (81.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
  • Altana inc
  • Taro pharmaceuticals usa inc
  • Pharmacia and upjohn co
  • Sanofi aventis us llc
  • Taro pharmaceuticals inc
Packagers
  • Allergan Inc.
  • Dermik Labs
  • Dispensing Solutions
  • E. Fougera and Co.
  • Lake Erie Medical and Surgical Supply
  • Nycomed Inc.
  • Pharmacia Inc.
  • Physicians Total Care Inc.
  • Taro Pharmaceuticals USA
Dosage Forms
FormRouteStrength
CreamTopical0.5 mg/1g
CreamTopical.05 %
OintmentTopical.05 %
CreamTopical0.5 mg/60g
CreamTopical5 mg/1g
OintmentTopical0.5 mg/1g
CreamTopical
OintmentTopical
Prices
Unit descriptionCostUnit
Psorcon 0.05% Ointment 60 gm Tube145.75USD tube
Psorcon 0.05% Cream 60 gm Tube137.58USD tube
Diflorasone Diacetate 0.05% Cream 60 gm Tube101.11USD tube
Diflorasone Diacetate 0.05% Ointment 60 gm Tube100.5USD tube
Diflorasone Diacetate 0.05% Cream 30 gm Tube52.81USD tube
Diflorasone Diacetate 0.05% Ointment 30 gm Tube52.29USD tube
Diflorasone Diacetate 0.05% Cream 15 gm Tube38.25USD tube
Diflorasone Diacetate 0.05% Ointment 15 gm Tube38.05USD tube
Psorcon 0.05% cream3.45USD g
Diflorasone 0.05% cream1.5USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP2.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0853 mg/mLALOGPS
logP1.91ALOGPS
logP1.34ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)12.42ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity102.32 m3·mol-1ChemAxon
Polarizability40.95 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9948
Blood Brain Barrier+0.971
Caco-2 permeable+0.747
P-glycoprotein substrateSubstrate0.7725
P-glycoprotein inhibitor INon-inhibitor0.7629
P-glycoprotein inhibitor IINon-inhibitor0.9002
Renal organic cation transporterNon-inhibitor0.8405
CYP450 2C9 substrateNon-substrate0.8789
CYP450 2D6 substrateNon-substrate0.9031
CYP450 3A4 substrateSubstrate0.6991
CYP450 1A2 substrateNon-inhibitor0.9313
CYP450 2C9 inhibitorNon-inhibitor0.9254
CYP450 2D6 inhibitorNon-inhibitor0.939
CYP450 2C19 inhibitorNon-inhibitor0.9234
CYP450 3A4 inhibitorNon-inhibitor0.7563
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8979
Ames testNon AMES toxic0.8509
CarcinogenicityNon-carcinogens0.9232
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3293 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9794
hERG inhibition (predictor II)Non-inhibitor0.6022
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Drugtargets2
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Pearce DJ, Spencer L, Hu J, Balkrishnan R, Fleischer AB Jr, Feldman SR: Class I topical corticosteroid use by psoriasis patients in an academic practice. J Dermatolog Treat. 2004 Jul;15(4):235-8. [Article]

Drug created at June 13, 2005 13:24 / Updated at December 04, 2021 10:45